Not Yet Recruiting
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
NCT07619066
- Conditions
- Advanced Breast Cancer, HER2 Mutation, Hormone Receptor Positive / HER2-negative Breast Cancer
- Locations
-
Not specified